Review top news and interview highlights from the week ending April 29, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The analysis of data from ZUMA-7 demonstrated significant efficacy for axi-cel over second-line standard treatment.
The real-world analysis addresses a clear gap in data from previous and ongoing cell therapy clinical trials.
The CIFFREO trial is underway in 11 countries but was halted in December 2021 amid safety concerns, including the death of a participant in a phase 1b study in the non-ambulatory cohort.
NKX101 and NKX019 have demonstrated preliminary signs of safety and efficacy in heavily pretreated patients with AML and NHL in 2 separate phase 1 studies.
In this late-breaking poster presented at the Tandem Meetings, investigators recommend that patients with primary or secondary central nervous system lymphoma be included in future clinical trials for CAR T-cell therapy.